Better’s Digital Therapeutic Demonstrates Effectiveness in Treating and Reversing Diabetes and Hypertension

Share Article

Individuals with diabetes lowered A1c by an average of -.8%; further improvement was observed following the intervention period. 91% of individuals with hypertension lowered blood pressure; systolic BP reduced by an average of -11.4 mmHg.

Our clinical trials in obesity, diabetes and now hypertension have demonstrated the effectiveness of our digital therapeutic in treating and reversing diseases that are common, costly and caused by the same short list of behaviors.

Better Therapeutics LLC, a company developing new forms of medicine to treat and reverse the most common diseases, presented clinical trial results demonstrating effectiveness in treating diabetes and hypertension. Today, at the annual conference of the American College of Lifestyle Medicine, Drs. David Katz, Chief Science Officer, and Mark Berman, Head of Health, presented data from two clinical trials making a case for the use of a novel digital therapeutic in the treatment of these common diseases.

Digital therapeutics are an emerging form of medicine that use software as the therapeutic agent in order to achieve clinically meaningful outcomes in patients. In a study published earlier this year, Better’s digitally delivered behavioral intervention demonstrated effectiveness in lowering blood sugar among individuals with type 2 diabetes. After 12 weeks of treatment, average A1c was reduced -.8%, and continued to improve after the intervention period to -1.5%. Results of the study were peer-reviewed and published earlier this year.

The company’s most recent study among individuals with hypertension demonstrated an average reduction in systolic blood pressure of -11.4 mmHg, more than two times the level of clinical meaningfulness. Among those with more severe hypertension (blood pressure >= 140/90), 85% reduced blood pressure a clinically meaningful amount and the average systolic reduction was -17.6 mmHg. The complete study will be published later this year and a copy can be requested by email to press@bettertherapeutics.io.

“Our clinical trials in obesity, diabetes and now hypertension have demonstrated the effectiveness of our digital therapeutic in treating and reversing diseases that are common, costly and caused by the same short list of behaviors,” said Kevin Appelbaum, Better’s Co-founder and CEO.

About Better Therapeutics
Better is developing new forms of medicine to treat and reverse common diseases like diabetes and heart disease by addressing root causes. Through value-based arrangements with innovative private health insurers, the company is working with individuals to reverse disease, while lowering costs by reducing the ongoing need for prescription medications. Concurrently, it is advancing the development of clinically validated, FDA cleared, physician prescribed digital therapeutics for cardio metabolic diseases. The company is headquartered in San Francisco, CA, with operations in Boston, MA and Nashville, TN. http://www.bettertherapeutics.io

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole Landberg
@Better_TX
Follow >
Better Therapeutics

Visit website